Accessibility Menu
Chugai Pharmaceutical logo

Chugai Pharmaceutical(OTC) CHGCF

Market Cap$69.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+191%
5 Year+20%
1 Year-15%
1 Month-8%
$43.68
+3.27%
+1.38Today
Chugai Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 42.292026-08-03
Chugai Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.61%USD 43.432026-07-27
1 month-8.21%USD 46.082026-07-02
3 month-20.96%USD 53.512026-05-05
Year to date-22.32%USD 54.452025-12-31
1 year-15.02%USD 49.772025-08-01
3 year+53.93%USD 27.482023-07-31
5 year+19.57%USD 35.372021-07-30
Since inception+191.18%USD 14.522004-04-22

Chugai Pharmaceutical Financials at a Glance

Market Cap

$69.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥1.35T

Net Income (TTM)

¥472.96B

EPS (TTM)

$1.86

P/E Ratio

22.79

Dividend

$0.87

Beta (Volatility)

0.14 (Low)

Price

$43.68

Volume

14,514

Open

$42.47

Previous Close

$43.68

Daily Range

$41.27 - $43.68

52-Week Range

$38.68 - $68.08

Estimated Earnings Date

Oct 27, 2026

CHGCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd. is a leading pharmaceutical company based in Tokyo, Japan, specializing in the research, development, manufacturing, and sale of innovative medicines. The company operates both domestically and internationally, with a strong presence in Europe, Taiwan, and China.

Products and Services
  • Innovative pharmaceuticals targeting oncology and autoimmune diseases
  • Research and development services for new drug formulations
  • Manufacturing and distribution of high-quality medicines
Growth Outlook
  • Recent quarterly revenue reached JPY 339.11 billion, indicating strong market demand
  • Net income for Q2 2026 was JPY 115.49 billion, showcasing profitability
  • Robust R&D investment of JPY 47.41 billion supports future product pipeline
Financial Highlights
  • Trailing twelve months (TTM) revenue of JPY 1.36 trillion reflects consistent growth
  • Net profit margin of 35.10% demonstrates effective cost management
  • Dividend yield of 3.11% offers attractive returns to shareholders
Chugai Pharmaceutical Co., Ltd. has established itself as a key player in the pharmaceutical industry, focusing on innovative solutions to address unmet medical needs. The company's commitment to research and development is evident in its significant investments, which are expected to drive future growth. Recent financial performance highlights a strong revenue base and profitability, making it an appealing option for investors interested in the healthcare sector. With a solid market position and a focus on innovation, Chugai is well-positioned for continued success in the evolving pharmaceutical landscape.
AI Generated • Jul 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7,872

CEO

Osamu Okuda

Website

www.chugai-pharm.co.jp

Headquarters

Tokyo, TY 103-8324, JP

CHGCF Financials

Key Financial Metrics (TTM)

Gross Margin

71.39%

Operating Margin

47.24%

Net Income Margin

35.10%

Return on Equity

24.02%

Return on Capital

28.77%

Return on Assets

19.24%

Earnings Yield

4.39%

Dividend Yield

2.05%

Payout Ratio

94.94%

Stock Overview

Market Cap

$69.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.65B

Volume

14.51K

Avg. Volume

5.86K

Financials (TTM)

Gross Profit

¥961.88B

Operating Income

¥674.36B

EBITDA

¥689.73B

Operating Cash Flow

¥454.56B

Capital Expenditure

-¥48.81B

Free Cash Flow

¥405.75B

Cash & ST Invst.

¥955.61B

Total Debt

¥17.57B

Chugai Pharmaceutical Performance Analysis

Chugai Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31JPY 9,579,323,8285.3%
20232023-12-31JPY 7,903,733,267-17.5%
20242024-12-31JPY 7,727,065,222-2.2%
20252025-12-31JPY 8,408,723,7578.8%
Chugai Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.5%
Q42025-12-312.6%
Q12026-03-31-6.6%
Q22026-06-304.7%
Chugai Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31JPY 1.733.2%
20232023-12-31JPY 1.41-18.7%
20242024-12-31JPY 1.5510.4%
20252025-12-31JPY 1.7613.5%
Chugai Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.1%
Q42025-12-3113.9%
Q12026-03-31-10.0%
Q22026-06-30-1.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

¥339.11B

+16.9%

Gross Profit

¥236.25B

+17.0%

Gross Margin

69.67%

N/A

Market Cap

$69.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.84M

N/A

Employees

7,872

N/A

Net Income

¥115.49B

+18.9%

EBITDA

¥159.41B

+16.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

¥955.61B

-7.0%

Total Debt

¥17.57B

+19072.5%

Accounts Receivable

¥379.14B

+19.7%

Inventory

¥315.28B

+33.9%

Long Term Debt

¥0.00

N/A

Short Term Debt

¥0.00

N/A

Return on Assets

19.24%

N/A

Return on Invested Capital

30.83%

N/A

Free Cash Flow

¥118.60B

+28.1%

Operating Cash Flow

¥127.12B

+6.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MKKGYMerck KGaA
$33.81+2.73%
MKGAFMerck KGaA
$170.60+3.39%
SOAGYSartorius Aktiengesellschaft
$52.72-0.04%
IPSEYIpsen S.A.
$45.71+1.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About CHGCF

What is the current price of Chugai Pharmaceutical?

Chugai Pharmaceutical is trading at $43.68 per share.

What is the 52-week range for Chugai Pharmaceutical?

Over the past 52 weeks, Chugai Pharmaceutical has traded between $38.68 and $68.08.

How much debt does Chugai Pharmaceutical have?

As of the most recent reporting period, Chugai Pharmaceutical reported total debt of ¥108.86M.

How much cash does Chugai Pharmaceutical have on hand?

Chugai Pharmaceutical reported ¥2.40B in cash and cash equivalents in its most recent financial results.

What is Chugai Pharmaceutical’s dividend yield?

Chugai Pharmaceutical currently has a dividend yield of 2.05%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services